Evidence map›Paper›PMID 28115237›Full record

ArticleNeuroscience letters2017

Initial characterization of behavior and ketamine response in a mouse knockout of the post-synaptic effector gene Anks1b.

Rachel M Enga, Ann C Rice, Pamela Weller, Mark A Subler, Daiyoon Lee, Chelsea P Hall, Jolene J Windle, Patrick M Beardsley, Edwin J van den Oord, Joseph L McClay

Open access · greenAbstract read
In one paragraph

Article in Neuroscience letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. ThePharmacogenomics · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Rachel M EngaDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA.
Ann C RiceDepartment of Neurology, Virginia Commonwealth University, Richmond, VA, USA.
Pamela WellerDepartment of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA.
Mark A SublerDepartment of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA.
Daiyoon LeeDepartment of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, VA, USA.
Chelsea P HallDepartment of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, VA, USA.
Jolene J WindleDepartment of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA.
Patrick M BeardsleyDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA; Center for Biomarker Research and Precision Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Edwin J van den OordCenter for Biomarker Research and Precision Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Joseph L McClayDepartment of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University, Richmond, VA, USA. Electronic address: jlmcclay@vcu.edu.
Virginia Commonwealth University · US

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Keri R Maher · 1985 to 2026
$51.0M
TRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI William L. Dewey · 1985 to 2026
$14.7M
NCI NIH HHS P30 CA016059NIDA NIH HHS T32 DA007027
6 · The paper itself

Abstract

The human ANKS1B gene encodes an activity-dependent effector of post-synaptic signaling. It was recently associated with neuropsychiatric phenotypes in genome-wide studies. While the biological function of ANKS1B has been partly elucidated, its role in behavior is poorly understood. Here, we breed and characterize a full knockout (KO) for murine Anks1b. We found that the homozygous KO genotype was partially lethal, showing significant deviation from expected segregation ratios at weaning. Behaviorally, KOs exhibited no difference in baseline acoustic startle response, but showed deficits in prepulse inhibition (PPI). KOs also exhibited locomotor hyperactivity and increased stereotypy at baseline. Administration of ketamine, a non-competitive NMDA-receptor antagonist, greatly exacerbated locomotor activity in the KOs at lower doses, but genotype groups were almost indistinguishable as dose increased. Stereotypy showed a complex response to ketamine in the KOs, with elevated stereotypy at lower doses and markedly less at high doses, compared to wild type. Our study is the first to probe the behavioral phenotypes associated with ablation of Anks1b. Deficits in PPI, locomotor hyperactivity, elevated stereotypy and altered response to NMDA receptor antagonism are murine behavioral outcomes with translational relevance for psychiatric disorders. These findings are also consistent with the role of Anks1b as an effector of glutamatergic signaling. As an intermediary between post-synaptic receptor stimulation and long-term changes to neuronal protein expression, further investigation of Anks1b is warranted.

Indexed as

Behavior, AnimalAnimalsIntracellular Signaling Peptides and ProteinsKetamineMice, KnockoutMotor ActivityPrepulse InhibitionReceptors, N-Methyl-D-AspartateReflex, StartleStereotyped BehaviorAnks1b protein, mouseIntracellular Signaling Peptides and ProteinsKetamineReceptors, N-Methyl-D-AspartateGlutamatergic signalingLocomotor activityNMDA receptorsPost-synaptic densitySensorimotor gating

Identifiers

PMID28115237
PMCPMC5305419
OpenAlexW2571572502

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.